Related Experiment Video
Updated: May 23, 2026
07:05
Quantifying Food Intake in Caenorhabditis elegans by Measuring Bacterial Clearance
Published on: February 23, 2024
LIPITENSION: Interplay between dyslipidemia and hypertension
Jamshed J Dalal1, T N C Padmanabhan, Piyush Jain
1Department of Cardiac Sciences, Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Andheri, Mumbai, India.
Indian Journal of Endocrinology and Metabolism
|April 4, 2012
Summary
Cardiovascular disease (CVD) risk increases globally, especially in India. This review highlights the combined impact of hypertension and dyslipidemia, termed
Area of Science:
- Cardiology
- Public Health
- Epidemiology
Background:
- Cardiovascular disease (CVD) burden is rising globally, posing a significant public health challenge, particularly in developing nations like India.
- Hypertension and dyslipidemia are primary contributors to CVD.
- Epidemiological studies indicate a 15-31% prevalence of co-existing hypertension and dyslipidemia.
Purpose of the Study:
- To review the co-existence and interplay of dyslipidemia and hypertension.
- To introduce the term 'LIPITENSION' for the concurrent presence of these two conditions.
- To emphasize the clinical significance of managing these co-existing risk factors.
Main Methods:
- Literature review focusing on epidemiological studies and clinical implications.
- Analysis of the synergistic adverse effects of combined hypertension and dyslipidemia on vascular endothelium.
- Synthesis of information to define and contextualize 'LIPITENSION'.
Main Results:
- The co-existence of hypertension and dyslipidemia significantly exacerbates atherosclerosis.
- This combined effect has a greater than additive negative impact on vascular health.
- The term 'LIPITENSION' is proposed to facilitate recognition and management.
Conclusions:
- The concurrent presence of hypertension and dyslipidemia ('LIPITENSION') represents a critical risk factor for CVD.
- Aggressive and combined management strategies are essential for preventing cardiovascular events.
- The term 'LIPITENSION' aims to improve clinical identification and treatment protocols.
Related Concept Videos
01:29Hypertension II: Pathophysiology
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
01:28Hypertension I: Introduction
Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:18Hypertension and Regulation of Blood Pressure
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
01:30Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...